Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency
The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2096-e2107
DOI: 10.1210/clinem/dgag153 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.04.2026. Verfasst von Yuka Oi-Yo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Muscle Strength, Dwarfism, Pituitary. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Foundation for Growth Science.
Abstract (Originalsprache)
Context
Once-weekly somapacitan is approved for treating adults with growth hormone deficiency. Phase 3 trials support its noninferiority to daily growth hormone (GH); however, its effect on comprehensive metabolic outcome, including muscle strength, during routine care, remains unclear.
Objective
To compare the metabolic and functional outcomes in patients who switched from daily GH to somapacitan with those who continued daily GH.
Methods
Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks. This study was conducted at a single-center providing routine endocrine management. Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH. Switching from daily GH to once-weekly somapacitan, or continuing daily treatment based on patient preference. The prespecified primary endpoint was the dual-energy X-ray absorptiometry-derived change in total lean mass from baseline to week 52. Exploratory endpoints included body composition, lipid profile, and physical performance.
Results
Baseline and week 52 insulin-like growth factor 1 standard deviation scores distributions were similar between the groups; yet the increase was greater with daily GH than with somapacitan. The primary endpoint showed no between-group difference (mean difference −0.2 kg; 95% CI −1.5 to 1.1). Somapacitan was associated with increased adiposity indices, yet it improved high-density lipoprotein-cholesterol. Exploratory analyses revealed improvements in handgrip strength and Timed Up and Go Test. No new safety concerns were observed.
Conclusion
In routine practice, switching to once-weekly somapacitan was associated with improved functional outcomes, despite less favorable adiposity trajectories, compared with daily therapy. Further studies are required to clarify long-term effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe 650-0017, Japan.
- Department of Nutrition, Kobe University Hospital, Kobe 650-0017, Japan.
- Faculty of Clinical Nutrition and Dietetics, Department of Clinical Nutrition and Dietetics, Konan Women's University, Kobe 658-0001, Japan.
- Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
ORCID-Profile: Yuka Oi-Yo, Shin Urai, Masaaki Yamamoto, Yuka Ohmachi, Hironori Bando, Genzo Iguchi, Yoshitada Sakai, Hidenori Fukuoka
Förderung
- Japan Society for the Promotion of Science
- Foundation for Growth Science
Zitieren
APA
Oi-Yo, Y., Urai, S., Yamamoto, M., Tomofuji, S., Ohmachi, Y., Sasaki, Y., Bando, H., Takahashi, M., Iguchi, G., Harada, R., Sakai, Y., & Fukuoka, H. (2026). Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2096-e2107. https://doi.org/10.1210/clinem/dgag153
Vancouver
Oi-Yo Y, Urai S, Yamamoto M, Tomofuji S, Ohmachi Y, Sasaki Y, et al. Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2096-e2107. doi:10.1210/clinem/dgag153
BibTeX
@article{OiYo2026,
author = {Oi-Yo, Yuka and Urai, Shin and Yamamoto, Masaaki and Tomofuji, Seiji and Ohmachi, Yuka and Sasaki, Yuriko and Bando, Hironori and Takahashi, Michiko and Iguchi, Genzo and Harada, Risa and Sakai, Yoshitada and Fukuoka, Hidenori},
title = {Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {9},
pages = {e2096--e2107},
doi = {10.1210/clinem/dgag153}
}
EUVIMED